If we are to escape from dilemmas such as Nice's fateful decision on Nexavar, it can only be by permitting additional revenue streams into the NHS, argues Janet Daley. Nice has made another of its fateful (or "fatal") decisions: the drug, Nexavor, which significantly prolongs the life of liver cancer patients, and is widely available in other countries, is not be used by the NHS because it is too expensive. So all those who might have benefited from it have effectively been told that, on accounting principles, they are not worth keeping alive. Nice is functioning as what the US...